Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I.

Crum-Cianflone NF, Sullivan E.

Infect Dis Ther. 2017 Sep;6(3):303-331. doi: 10.1007/s40121-017-0166-x. Epub 2017 Aug 4. Review.

2.

Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults.

Ohtola JA, Saul-McBeth JL, Iyer AS, Leggat DJ, Khuder SA, Khaskhely NM, Westerink MJ.

J AIDS Clin Res. 2016 Mar;7(3). pii: 556. Epub 2016 Mar 14.

3.

HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV).

Meiring S, Cohen C, Quan V, de Gouveia L, Feldman C, Karstaedt A, Klugman KP, Madhi SA, Rabie H, Sriruttan C, von Gottberg A; GERMS-SA.

PLoS One. 2016 Feb 10;11(2):e0149104. doi: 10.1371/journal.pone.0149104. eCollection 2016.

4.

Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.

Cheng A, Chang SY, Tsai MS, Su YC, Liu WC, Sun HY, Hung CC.

J Int AIDS Soc. 2016 Jan 29;19(1):20631. doi: 10.7448/IAS.19.1.20631. eCollection 2016.

5.

High Streptococcus pneumoniae colonization prevalence among HIV-infected Kenyan parents in the year before pneumococcal conjugate vaccine introduction.

Conklin LM, Bigogo G, Jagero G, Hampton L, Junghae M, da Gloria Carvalho M, Pimenta F, Beall B, Taylor T, Plikaytis B, Laserson KF, Vulule J, Van Beneden C, Whitney CG, Breiman RF, Feikin DR.

BMC Infect Dis. 2016 Jan 16;16:18. doi: 10.1186/s12879-015-1312-2.

6.

Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine.

Yildirim I, Shea KM, Pelton SI.

Infect Dis Clin North Am. 2015 Dec;29(4):679-97. doi: 10.1016/j.idc.2015.07.009. Review.

7.

Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa.

Tempia S, Wolter N, Cohen C, Walaza S, von Mollendorf C, Cohen AL, Moyes J, de Gouveia L, Nzenze S, Treurnicht F, Venter M, Groome MJ, Madhi SA, von Gottberg A.

BMC Infect Dis. 2015 Oct 26;15:450. doi: 10.1186/s12879-015-1198-z.

8.

Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program.

Moore MR, Whitney CG.

Emerg Infect Dis. 2015 Sep;21(9):1551-6. doi: 10.3201/eid2109.150395.

9.

Acute suppurative parotitis caused by Streptococcus pneumoniae in an HIV-infected man.

Guzman Vinasco L, Bares S, Sandkovsky U.

BMJ Case Rep. 2015 Mar 2;2015. pii: bcr2014209082. doi: 10.1136/bcr-2014-209082.

10.

Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Lee KY, Tsai MS, Kuo KC, Tsai JC, Sun HY, Cheng AC, Chang SY, Lee CH, Hung CC.

Hum Vaccin Immunother. 2014;10(12):3700-10. doi: 10.4161/hv.32247. Review.

11.

Delayed reconstitution of B cell immunity to pneumococcus in HIV-infected Malawian children on antiretroviral therapy.

Iwajomo OH, Moons P, Nkhata R, Mzinza D, Ogunniyi AD, Williams NA, Heyderman RS, Finn A.

J Infect. 2015 Jun;70(6):616-23. doi: 10.1016/j.jinf.2014.10.011. Epub 2014 Nov 1.

12.

Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.

Bamford A, Kelleher P, Lyall H, Haston M, Zancolli M, Goldblatt D, Kampmann B.

AIDS. 2014 Sep 10;28(14):2033-43. doi: 10.1097/QAD.0000000000000385.

13.

Lifestyle risk factors for invasive pneumococcal disease: a systematic review.

Cruickshank HC, Jefferies JM, Clarke SC.

BMJ Open. 2014 Jun 20;4(6):e005224. doi: 10.1136/bmjopen-2014-005224. Review.

14.

Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore.

Eng P, Lim LH, Loo CM, Low JA, Tan C, Tan EK, Wong SY, Setia S.

Int J Gen Med. 2014 Mar 31;7:179-91. doi: 10.2147/IJGM.S54963. eCollection 2014. Review.

15.

Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization.

Loo JD, Conklin L, Fleming-Dutra KE, Knoll MD, Park DE, Kirk J, Goldblatt D, O'Brien KL, Whitney CG.

Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S161-71. doi: 10.1097/INF.0000000000000084. Review.

16.

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O'Brien KL, Moore MR; Serotype Replacement Study Group.

PLoS Med. 2013;10(9):e1001517. doi: 10.1371/journal.pmed.1001517. Epub 2013 Sep 24.

17.

U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.

Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG.

N Engl J Med. 2013 Jul 11;369(2):155-63. doi: 10.1056/NEJMoa1209165.

18.

Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.

Smith KJ, Nowalk MP, Raymund M, Zimmerman RK.

Vaccine. 2013 Aug 20;31(37):3950-6. doi: 10.1016/j.vaccine.2013.06.037. Epub 2013 Jun 24.

19.

Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Nunes MC, Madhi SA.

Hum Vaccin Immunother. 2012 Feb;8(2):161-73. doi: 10.4161/hv.18432. Epub 2012 Feb 1. Review.

20.

Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program.

Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Kuwanda L, Karstaedt AS, Klugman KP, Madhi SA.

PLoS One. 2011;6(11):e27929. doi: 10.1371/journal.pone.0027929. Epub 2011 Nov 28.

Supplemental Content

Support Center